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ABSTRACT  
For a long time scientists have tried to describe disorders are due to genetic as well as environmental factors. In the past few years, revolution in 
technology that has made it possible to decipher the human genome. Epigenetics explains the capability gene expression regulation without 
modifying the genetic sequence. Epigenetic mechanisms are rooted changes in molecules, or nuclear characteristics that can alter gene expression 
without altering the sequences of DNA, i.e. DNA methylation, histone modification, and non-coding RNAs. Learning of the fundamental epigenetic 
modification allowing gene expression as well as cellular phenotype are advanced that novel insights into the epigenetic control of cardiovascular 
disease, hepatic disease, as well as chronic kidney disease are now emerging. From a half of century ago, in human disease the role of epigenetics 
has been considered. This subject has attracted many interests in the past decade, especially in complicated diseases like cardiovascular disease, 
hepatic disease as well as chronic kidney disease. This review first illustrates the history and classification of epigenetic modifications and the 
factors (i.e. genetic, environment, dietary, thought process and lifestyle) affecting to the epigenetics mechanisms. Likewise, the epigenetics role in 
human diseases is think out by targeting on some diseases and at the end, we have given the future perspective of this field.  This review article 
provides concepts with some examples to describe a broad view of distinct aspects of epigenetics in biology and human diseases.  
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In case of modern medicine genetics field has become an 
essential part in the 50 years therefore the structural model 
of DNA is illustrated by Watson and Crick. Advances have 
been made in identifying specific mutations related with 
some human diseases like cystic fibrosis as well as 
Huntington’s chorea. Additional advances such as Human 
Genome Project, are giving new opportunities to develop 
better diagnostic tools and targeted gene therapies.1The 
Epigenetics term itself describes, as ‘epi’ means above or 
over in Greek, but it was Conrad Waddington who, in 1940, 
provided the first broad and operational definition of 
epigenetics it is nothing but the unusual interactions in genes 
and their products, that bring the phenotype into being”.2 
Conrad Waddington in the 1950s states that ‘‘an epigenetic 
feature is a stably heritable phenotype results in changes in a 
chromosome without changing the sequences in the DNA’’.3 
Epigenetics and Epigenomics: 
The epigenetic definitions state that the whole DNA content 
is exactly similar in somatic cells of one species, though gene 
expressions patterns have number of differences in various 
cell types that can be inborn clonally.4 Epigenetics have an 
tremendous effect on medicine. Epigenetics is nothing but 
the  study of heritable alteration in gene functions that do 
not changes the DNA sequence but it can provide a one more 
layer of transcriptional control that control how genes are 
explicit.5 
The term “epigenetics” has been defined for decades as a 
alteration in the state of expression of a gene (or a feature) 
that does not contain a mutation but that is nonetheless 
rooted (at least through a mitotic division) in the absence of 
the signal or event that begins the change, the newer term 
“epigenomics”  for  our  knowledge never been formally 
defined” Epigenomics” on the genome-wide level search 
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communities has been widely accepted operationally  to 
indicate studies that focuses on the analysis of DNA 
methylation, histone modifications, and noncoding RNAs.6 
 
Figure1: Effects of epigenetics on epigenomics and 
occurrence of diseases.7 
An Epigenetics mechanism describes that enable cells to 
respond quickly to environmental alteration and provide a 
link between genes and environment. Variation in the 
epigenetic modification of genes can describe a larger part of 
the phenotypic fluctuations observed in humans than 
differences in genotype alone.8 The current work focuses on 
epigenetic mechanisms of epigenetics in disease condition,  
for normal growth, development and  homeostasis epigenetic 
processes are essential.9 A combination of stochastic events 
including both genetic as well as environmental factors (e.g., 
diet, smoking, obesity and stress), which, at the molecular 
level, cause alteration in gene expression and the aging 
process of organism. For example, aging of the brain is 
accompanied by changes of gene expression encoding 
proteins involved in stress responses, inflammatory 
responses and neuropeptide metabolism while the elderly 
heart has an altered transcription profile that leads to 
disability of cardiac function.10 
In the past decade various studies have strongly implicated 
epigenetic mechanisms in controlling the gene expression 
changes regulating several aging-related diseases like cancer 
and cardiac failure and in promoting the gene expression 
changes are responsible for the aging process of different 
tissues. Therefore, during aging process cells more prone to 
the transcriptional changes responsible for aging-related 
diseases due to the alteration of epigenetic mechanism. In 
this review, we will discuss the possible role of epigenetics in 
controlling the onset of two aging-related diseases like 
cancer and cardiovascular disease.11 
Mechanism of Epigenetics 
The major epigenetic controlling mechanisms of mammalian 
cells include- 
1. DNA methylation, 
2.  posttranslational histone modifications (PTMs) and 
3.  RNA based mechanisms including those controlled by 
the better characterized small non-coding RNAs 
(sncRNAs).  
 MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) 
are newly showing their potential as biomarkers. 
1. DNA methylation:- 
The DNA methylation is nothing but fairly stable epigenetic 
changes which consist of the covalent binding of a methyl 
group to the 5’ carbon of cytosine. The CpG-rich islands 
contain 40% of genes and up to 70% of all CpG dinucleotides 
in the genome are methylated. Regulation of gene expression 
by changing the transcriptional machinery accessibility to 
DNA is the significant function of DNA methylation.12  
High stability of DNA methylation status and it not only 
serves as a special epigenetic memory of specific cells over a 
all periods in the cell cycle but also regulate the gene 
expression and histone codes activity. Acceleration of DNA 
methylation process accelerated at CpG sites and mediated 
by DNA methyl transferase enzymes such as DNMT1, 
DNMT3a, and DNMT3b.S-adenosyl methionine act as an 
important methyl group donor inside the cell.  Folic acid and 
B12 play the important roles in re-methylation or the 
attraction of de-methylated form of S-adenosyl methionine 
via active and passive mechanisms.13, 14 In the initial years of 
life level of nutrition could impact on the DNA methylation 




Figure 2: DNA methylation  16 
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2. Histone modifications:- 
Histone modification regulating the gene expression via 
chromatin remodeling and it includes acetylation, methylation, 
phosphorylation, ribosylation, ubiquitylation, sumoylation, 
and citrullination. Acetylation is has mediated through five 
families of mammalian histone acetyltransferase enzymes.17 
Histone are that are essential components of nucleosomes 
structure in eukaryotic cells it is nothing but a small (11–22 
kDa) nuclear proteins hence DNA wraps around an octamer of 
the core histones H2A, H2B, H3, and H4, it helps in 
constructing the fundamental unit of chromatin.18 Due to 
PTMs, histone proteins play a essential role in the regulation 
of chromatin which control the binding of other proteins 
called readers. This evidence gives a idea that extracellular 
histones contribute to human disease because they are 
cytotoxic for a wide array of human cells and human tissues19 
by performing several in vitro and in vivo experiments that 
showed after binding to phospholipids circulating histone can 
damage cell membranes, disruption of Ca2+ influx is produced 
and it leads to the release of other intracellular mediators that 




Figure3: Histone modification21 
 
3. miRNAs:- 
miRNAs are a class of conserved, short (18–24nt). At the 
posttranscriptional level non-coding RNAs that have ability to 
control the gene expression in distinct biological networks. In 
recent years miRNAs have potential to be used as 
biomarkers.22 Recent studies is proposing epigenetic 
biomarkers mainly based upon circulating miRNAs as 
biomarkers of various disease conditions [e.g., cardiac disease, 
Neurodegenerative and psychological disorders, chronic 
kidney disease and liver disease, among others]. 
miRNAs are considered as a member of the noncoding RNAs 
about 17 to 25 nucleotides that can carried out a various 
biological activities. About 60% of protein-coding genes in 
human is regulated by the miRNAs, 23 and these miRNAs are 
adjusted epigenetically adjusted by methylation in CpG islands 
or histone modifications or both of them.24, 25 
 
 
Figure 4: miRNA26 
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Factors affecting epigenetics 
There are number of factors which impact on epigenetics but 
mainly five factors which alter the epigenetic mechanism 
includes  
i. Genetic factors 
ii. Dietary factors 
iii. Environmental factors 
iv. Thought process 
v. Lifestyle 
i. Genetic factors :- 
 Heredity: - The transfer of genes from one generation to 
the next generation. You inherit your parents' genes is 
known as heredity. It is helps to make you the person you 
are today: for example- short or tall, with black hair or 
blond, with brown eyes or blue.27 
ii. Dietary factors:- 
 Diet also responsible for epigenetic changes. Dietary 
components have potential to overcome the  disease and 
promote overall  individuals health.28,29,30,31 
 Epigenetic diet compounds - 
Dietary Polyphenols: such as tea polyphenols (i.e., 
epicatechin, epicatechin-3-gallate, epigallocatechin and 
epigallocatechin-3-gallate), 
Resveratrol and curcumin: It act as histone modifiers and it 
has potential as anticancer therapeutic as well as 
chemopreventive agents and have ability to inhibit the DNA 
methylation process.   
Isoflavones: such as genistein are found in soybeans, fava 
beans and kudzu and it have anticancer properties that 
involved in DNA methylation process.   
Isothiocyanates:  such as sulforaphane can impact on the 
epigenome.  
Other dietary factors: Those dietary components found in 
Brazilian nuts, chicken, cereals, coffee, cashews, garlic, parsley, 
milk thistle and rosemary have a epigenetic targets in cancer. 
Also have beneficial effects on the epigenome, are related with 
harmful epigenetic modifications.32  
iii. Environmental factors :- 
 “Environmental factors also responsible for the 
epigenetic changes.33 for example - vitamin B may defend 
against  epigenetic effects on pollution and also  prohibit 
the harmful effects that particular matter has on the 
body.34 
 Numerous environmental factors that have been 
associated with either global or site-specific DNA 
methylation alterations. The field of epigenetics has 
mainly focused on environmental factors such as 
nutrients and chemical contaminants.35 
  Recently life nutrition also  produces long-term changes 
in DNA methylation that impact on individual health as 
well as age-related diseases all over life.36,37 
 Psychological stress  studies have indicated that DNA 
methylation is susceptible to stressful environmental 
exposures in early development as well as later in 
life.38,39,40,41,42,43 
 
iv. Thought process:- 
 A life of happiness and positive thoughts change future 
generations. Our thoughts and actions can alter the 
epigenetic mechanism.  
 It's been shown  just thinking about something can cause 
your brain to release neurotransmitters, chemical 
messengers that allow it to communicate with parts of 
itself and your nervous system.44 
V.      Lifestyle:- 
  Various lifestyle factors such as nutrition, behavior, 
stress, physical activity, working habits, smoking and 
alcohol consumption. Environmental and lifestyle factors 
may alter the  epigenetic mechanisms.45 
 These factors leave epigenetic marks on our DNA that 
leads to the alteration of  gene expression.46 
 Epigenetics in  Cardiovascular Disease  
Recent data associated DNA methylation, as measured in 
peripheral blood leukocytes; with clinical cardiovascular 
disease47 found lower DNA methylation content in 
peripheral blood leukocytes from patients with 
atherosclerotic cardiovascular disease.  From the aging study 
it has been found that lower LINE-1 methylation in 
peripheral blood leukocytes is a predictor of incidence and 
mortality from ischemic heart disease and stroke.48 Global 
methylation measures gives average estimates of 
methylation across the genome do not have the resolution 
needed to target individual genes or gene sequences 
responsible for cardiovascular disease.49  
i. Heart failure:- 
Genetic predisposition and multiple environmental factors 
results in heart failure. In a patient with HF, Movassagh and 
colleagues reported that three angiogenesis-related genes 
were disccriminatory methylated. In the last stage of due to 
the altered epigenomics of the three genes may reflect 
common epigenetic pathways in vasculature and heart 
remodeling.50 In case of heart failure histone modifications 
and Micro-RNAs also have significant importance in 
epigenetics.51, 52  
ii. Hypertension:- 
One of the biggest risk factor for cardiovascular disease 
development is hypertension. Hypertension is not effectively 
overcome in most of the patients which leads to many 
cardiovascular complications. Complex interactions between 
different environmental factors and genes results in 
hypertension and epigenetic mechanism is implemented to 
treat the hypertension.53,54 Number of factors causing 
hypertension such as autonomic, renal, vessel 
diameter/compliance and neuroendocrine. 
iii. Congenital Heart Disease 
Congenital heart disease (CHD) represents a large proportion 
of significant birth defects, occurring in approximately 8 per 
1000 live births.55 Monogenic causes have been identified but 
most CHD is considered to be multifactorial with phenotypic 
differences noted between individuals in the same family or 
even with the same genetic defect (e.g. trisomy 21 where only 
~50% of individuals are born with CHD. A possible role for 
epigenetics in the etiology of CHD could be the dysregulation of 
DNA methylation during different stages of embryonic growth 
that could lead to the inappropriate silencing of tissue-specific 
gene expression and a resulting increased risk for cardiac 
malformation.56  
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 Epigenetics in  liver Disease  
Alteration in  epigenetics  consequently promote  a number of 
human diseases for example- fetal, and liver diseases ,alcohol 
spectrum disorders ,various types of cancer, neuropsychiatric 
disorders.57 The second  largest organ in the body is  liver 
which performs a various  biological functions. The common 
liver diseases are alcohol related and non-alcohol related liver 
diseases, viral-mediated liver diseases (Hepatitis A, B and C), 
fatty liver disease, Chronic liver diseases which needs long-
term therapy.58 Effective treatment and prevention is 
necessary to reduce the mortality and economic burden 
caused by the liver diseases worldwide. Epigenetic regulatory 
mechanisms offer new therapeutic potential to treat these 
diseases.  
i. Hepatocellular Carcinoma 
In the world 250,000 to 1 million deaths annually  are only 
because of  hepatocellular Carcinoma (HCC) is the fifth most 
common cancer in the world that causes.59 There are number 
of risk factors for hepatocellular carcinoma including diabetes, 
and obesity, dietary exposure to aflatoxins ,hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infections, smoking, 
alcohol.60 Epigenetic changes causes HCC metastasis, DNA 
methylation,  histone modification, invasion, and 
dissemination encompass noncoding RNAs regulation and all 
these  changes are associated with initiation and progression 
of hepatocellular carcinoma. 61                                               
ii. Liver Fibrosis:- 
Recently it is  well documented that cellular phenotype is at 
least in part under control of chromatin configuration at key 
regulatory genes, with the help of epigenetic mechanisms.62 
‘epigenetics’ describes that reversible changes in gene 
expression that can be inherited via cell division that do not 
involve alterations of DNA sequence.63 Epigenetic mechanisms 
regulate the chromatin structure, modifications and the 
initiation of transcription and their co-factors that dictate the 
rate at which a gene is actively transcribed.64,65,66,67 Here, we 
consider the epigenetic mechanisms involved in the 
pathogenesis of liver fibrosis, as well as examine recent 
advancements, approaches and strategies used in the field of  
epigenetic for the treatment of liver fibrosis.68 
iii. Alcoholic Liver Disease:- 
In recent studies, it has been documented how epigenetic 
factors can impact on the function and expression of several 
genes.69 Alcohol consumption is responsible for 3.8% of global 
mortality and 4.6% of disability-adjusted life-years (DA-LYs) 
lost due to premature death. From the meta-analysis it has 
been found that risks of mortality is increased from liver 
cirrhosis among men and women drinking 12-24 g of ethanol 
per day.70 Due to the excessive consumption of alcohol it 
causes exposes the liver cells exposed to a elevated levels of 
ethanol, which can lead to a class of clinical conditions 
identified as alcoholic liver disease (ALD).71 
Identification of epigenetic factors can be important not only 
for the screening of individuals at risk but also for the study of 
the epigenetic modification mechanisms underlying ALD.72 
 Epigenetics in  kidney diseases  
From the emerging evidence recommend that epigenetic 
changes are involved in the pathogenesis of diseases 
predisposing to chronic kidney disease (CKD). DNA 
hypermethylation has been associated with predisposition to, 
and progression of, atherosclerosis.73 A recent study DNA 
methylation levels in more than 14,000 genes between 
African-American end stage renal disease patients and his 
panic diabetes it shows   that DNA methylation differences 
were related with disease treatment.74 By changing the DNA 
methylation and histone acetylation epigenetic modulations of 
gene expression that might predispose to hypertension.75  
Based on the number of experimental studies it describes  that 
local, gene-specific alterations in DNA methylation may play an 
essential role in the treatment  of chronic kidney disease. From 
some evidence it was recommend that RNA interference is 
mainly essential for the development and progression of 
kidney disease.76 
i. Renal  cancer:-   
Over the last three decades renal cancer rising steadily and 
currently, it is 9th most common cancer in Europe.77 The 
diagnosis of renal cell cancer depends upon early detection of 
the tumor. Sometimes, clinical signs and symptoms are often 
not useful in an early prognosis of cancer, therefore the classic 
symptoms like haematuria, palpable flank mass and pain and 
are generally related with advanced stage of the disease.78.79, 80 
Arai E, 200981 reported that more malignant renal cancer is 
generated mainly due to the   alterations of DNA methylation 
in the precancerous kidney cortex tissue. Recently, it is 
admitted that DNA methylation   is the interplay between 
genetics and epigenetics that leads to tumour genesis and the 
development of cancer. This interplay have recently been 
elegantly demonstrated by 82 who identified mutations in 
genes that encode enzymes, alter chromatin structure and 
transcriptional control and therefore which demethylate or 
methylate key lysine residues of histones and it leads to the 
development of renal cell cancer.82 
Epigenetic mechanisms can be involved in the treatment of 
these neoplasms as well.83  
ii. Chronic Kidney Disease (CKD)   
There is considerable evidence showing the role of epigenetic 
mechanisms in the development of chronic kidney disease. 
Difference in DNA methylation pattern between normal and 
diseased kidneys identified in renal fibroblasts is noticed in 
previous study.84 Fibroblast multiplication is regulated by DNA 
methylation and leads to renal fibrogenesis. For example- The 
study of experimental murine models treated with 5-
azacytidine, it results in protection from renal fibrosis. In also 
demonstrated that hypermethylation of RAS protein activator 
like-1 was related with the renal fibrogenesis.84 various 
histone modifications in the human kidney have not been 
assessed with reference to chronic kidney disease. 
Future Prospective: 
In an individual’s lifetime DNA methylation and histone 
modifications might help to describes how environmental and 
lifestyle factors can impose aberrant gene expression patterns. 
For example, in the pathogenesis of cardiac lesions like, among 
others, atherosclerosis, arrhythmias, thrombosis and left 
ventricular dysfunction,  DNA and histones play essential roles 
by reducing the DNA-histone complex may constitute a viable 
goal for prevention of  various cardiac  complications.85 New 
approaches have  brought different clinical trials and have 
been explored recently  targeted  for the treatment of 
cardiovascular disease, liver disease and renal disease.86 
However, a  detailed genetic background evaluation helps the 
physicians to design the best therapeutic approach for each 
disease. For example - microRNAs involved in the pro-
inflammatory switch in macrophages and Kupffer cells will be 
more efficient and then a steroid-based treatment and will 
bare less side effects. Moreover, it has to be considered that 
epigenetic factors can be regulated by environmental factors, 
i.e. diet and medications, and since represent an ideal genetic 
therapy target. 
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Discussion: 
At the transcriptional and post-transcriptional levels or at the 
translation level and post-translational modifications 
epigenetic mechanisms can influence the gene activity. 
Potentially broad spectrum effects of epigenetic mechanism 
can be affected by both genetic and environmental factors 
could results in more varieties of cell differentiations, 
morphogenesis, variability, and adaptability of an organism.87 
The epigenetics covers the DNA modifications, histones and 
DNA-binding proteins, which are important in regulating 
changes in chromatin structure without any alteration in the 
sequence of nucleotide in DNA. Also, these alterations could be 
transferred from one generation to the next generation. The 
overall studies have shown that exercise and  lifestyle 
modifications including nutritional habits  are first protective 
measures for decreasing the risk of disease.88  In the 
pathogenesis of cardiovascular disease, hepatic disease and 
renal disease Non-coding RNAs were found to be essential and 
it also offers the possibility of operating as diagnostic and 
prognostic biomarkers.89 To improve our understanding of the 
involvement of lncRNA in regulating gene expression changes 
underlying heart, liver as well as kidney failure further studies 
on epigenetics is needed.88 
Conclusion: 
The epigenetics controlling the alteration in gene expression 
which influence on many different human cardiac, hepatic and 
renal diseases. Epigenetics helps to explain the complex 
interactions between genes and environment and 
understanding of disease by providing a new conceptual 
framework.  Over the life course epigenetic factors potently 
influence epigenetic variations and changes in gene 
expression. Epigenetic mechanisms in various diseases play a 
significant role in controlling the altered gene expression, 
which is also critical for disease development. These epigenetic 
modifications may serve as signatures to diagnose the disease 
and also may provide a promising scope to develop new drug 
targets to treat these diseases. 
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